Vertaling van "usd m net income from continuing " (Nederlands → Frans) :

Q3 2009 Q3 2008 Change USD m USD m USD m Net income from continuing operations 2 112 2 082 30 Fair value adjustments on financial instruments, net of taxes 124 –221 345 Net actuarial losses from defined benefit plans, net of taxes –733 –790 57 Novartis share of equity recognized by associated companies, net of taxes 37 –176 213
T3 2009 T3 2008 Variation M USD M USD M USD Résultat net des activités poursuivies 2 112 2 082 30 Ajustement des instruments financiers à leur juste valeur, nets d’impôts 124 –221 345

Q2 2009 Q2 2008 Change USD m USD m USD m Net income from continuing operations 2 044 2 266 –222 Fair value adjustments on financial instruments, net of taxes 79 13 66 Net actuarial gains from defined benefit plans, net of taxes 610 506 104 Novartis share of equity recognized by associated companies, net of taxes –19 –19
Part de Novartis aux capitaux propres comptabilisée par les sociétés associées, nette d’impôts –19 –19 Effets des écarts de conversion 1 415 –11 1 426 Montants liés aux activités abandonnées –6 6 Produits et charges comptabilisés au bilan 4 129 2 768 1 361 Attribuable aux: Actionnaires de Novartis AG 4 108 2 764 1 344

H1 2009 H1 2008 Change USD m USD m USD m Net income from continuing operations 4 019 4 574 –555 Fair value adjustments on financial instruments, net of taxes 36 –77 113 Net actuarial losses from defined benefit plans, net of taxes –55 –158 103 Novartis share of equity recognized by associated companies, net of taxes –86 –13 –73
Part de Novartis aux capitaux propres comptabilisée par les sociétés associées, nette d’impôts –86 –13 –73 Effets des écarts de conversion 12 1 365 –1 353 Montants liés aux activités abandonnées 9 –9 Produits et charges comptabilisés au bilan 3 926 5 700 –1 774 Attribuable aux: Actionnaires de Novartis AG 3 896 5 691 –1 795

2009 2008 Change USD m USD m USD m Net income from continuing operations 8 454 8 163 291 Fair value adjustments on financial instruments, net of taxes 93 –510 603 Net actuarial gains/losses from defined benefit plans, net of taxes 949 –2 140 3 089
T4 2009 T4 2008 Variation M USD M USD M USD Résultat net des activités poursuivies 2 323 1 507 816 Variation de juste valeur sur instruments financiers, nette d'impôts –67 –212 145

2008 2007 Change USD m USD m USD m Net income from continuing operations 8 163 6 540 1 623 Fair value adjustments on financial instruments –510 1 –511 Actuarial losses/gains from defined benefit plans, net –2 140 450 –2 590 Novartis share of equity recognized by associated companies –201 150 –351
2008 2007 Variation M USD M USD M USD Résultat net des activités poursuivies 8 163 6 540 1 623 Ajustement des instruments financiers à leur juste valeur –510 1 –511 Pertes/gains actuariels des régimes à prestations définies, nets –2 140 450 –2 590 Part de Novartis aux capitaux propres comptabilisée par les sociétés associées –201 150 –351

Q4 2008 Q4 2007 Change USD m USD m USD m Net income from continuing operations 1 507 931 576 Fair value adjustments on financial instruments –212 –10 –202 Actuarial losses from defined benefit plans, net –1 192 –591 –601 Novartis share of equity recognized by associated companies –12 37 –49
T4 2008 T4 2007 Variation M USD M USD M USD Résultat net des activités poursuivies 1 507 931 576 Ajustement des instruments financiers à leur juste valeur –212 –10 –202

YTD 2009 YTD 2008 Change USD m USD m USD m Net income from continuing operations 6 131 6 656 –525 Reversal of non-cash items Taxes 1 099 1 084 15
M USD M USD M USD Résultat net des activités poursuivies 6 131 6 656 –525 Annulation d’éléments non monétaires Impôts 1 099 1 084 15

31-okt-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer
31-oct.-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus